Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

The History of ACE Inhibitors in Scleroderma Renal Crisis

Ruth Jessen Hickman, MD  |  Issue: February 2021  |  February 16, 2021

Risk Factors

Although the exact incidence is unclear, it’s now thought that scleroderma renal crisis affects around 2–15% of scleroderma patients, with typical onset within the first three to five years after diagnosis.12

Dr. Steen and other researchers have identified risk factors for scleroderma renal crisis. These include high-dose steroids, worsening skin symptoms, positivity for anti-RNA polymerase III antibodies and new anemia or cardiac events. Scleroderma renal crisis is also much more common in patients with the diffuse cutaneous form of the disease.12

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The presence of one or more of these risk factors can provide diagnostic clues about scleroderma renal crisis. Patients usually present with malignant hypertension but may also be normotensive (though with increased blood pressure from their personal baseline). Patients have rising creatinine levels, low urine output, and often have microangiopathic hemolytic anemia.12

Diagnosing scleroderma renal crisis can sometimes be a challenge, particularly if it is the first presenting symptom of scleroderma. It is sometimes misdiagnosed as thrombotic thrombocytopenic purpura, as hemolytic uremic syndrome or as atypical hemolytic uremic syndrome. Anti-neutrophil cytoplasmic antibody–associated vasculitis is another potential cause of acute renal failure in a patient with scleroderma, and it requires different treatment.12 But Dr. Steen notes, “Even if there is another possible diagnosis, I feel that if they have scleroderma, they should be treated with an ACE inhibitor until another diagnosis is confirmed, because it is both potentially kidney saving and lifesaving.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Current management of scleroderma renal crisis requires early and aggressive intervention with ACE inhibitors and, if needed, with other medications, such as calcium channel blockers, and dialysis. Beta blockers should be avoided, because they exacerbate Raynaud’s phenomenon. If renal function has not returned within a year of continued ACE inhibitors, renal transplantation is the next step.12 

Outcomes & Ongoing Research

Although the introduction of ACE inhibitors dramatically and positively changed outcomes of scleroderma renal crisis, some patients still do die or require long-term dialysis. In a study of 145 patients with scleroderma renal crisis treated with inhibitors, 38% of patients had poor outcomes.14 Older, debilitated patients and those with congestive heart failure also tend to do worse, as do patients presenting with greater than 3mg/dl creatinine.15 Dr. Steen explains, “Some of them don’t do well because they weren’t diagnosed promptly and accurately, and some don’t do well because the disease is so resistant.” 

Dr. Steen emphasizes the need for both physician and patient education. Physicians need to be on the lookout for scleroderma renal crisis and recognize it as an urgent situation that requires immediate treatment. Particularly for high risk groups, it’s critical that patients understand the potential symptoms of high blood pressure, monitor their pressure at home and seek immediate treatment when necessary.

Since the advent of ACE inhibitors and the improved survival of renal crisis, lung involvement with pulmonary hypertension and pulmonary fibrosis has surpassed kidney disease as the leading cause of death in scleroderma patients.16 Yet scleroderma renal crisis still remains a major risk factor for mortality in scleroderma patients. After the initial improvement with introduction of the ACE inhibitors in the 1980s, the prognosis has not changed much.

Research continues for agents that might improve outcomes. Dr. Steen points out that it is difficult to perform good clinical trials of scleroderma renal crisis because the disease manifests so quickly. Researchers are currently exploring whether the addition of endothelin-1 receptor blocker medications—now used to treat digital ulcers and pulmonary hypertension in scleroderma—might also improve outcomes in scleroderma renal crisis when used in addition to ACE inhibitors.17

Page: 1 2 3 4 5 | Single Page
Share: 

Filed under:ConditionsSystemic Sclerosis Tagged with:Lost & FoundRenal disease

Related Articles
    Diffuse Scleroderma: A 1991 Case Through the Lens of Today

    Diffuse Scleroderma: A 1991 Case Through the Lens of Today

    February 17, 2018

    The year was 1991. It was my first Tuesday as a rheumatology fellow at the University of Pittsburgh’s Presbyterian Hospital. Navigating a maze of buildings and hallways, I delivered myself to the entrance to the scleroderma clinic. Running late and not knowing whether there was a separate entrance for staff, I clicked open the door….

    Can Technology Help Solve Scleroderma Renal Crisis?

    December 1, 2010

    A case study in using the Internet to facilitate rare disease research

    Case Report: A Patient Develops Scleroderma Renal Crisis

    October 18, 2019

    Scleroderma renal crisis (SRC) is a life-threatening complication of systemic sclerosis. SRC occurs in 2–15% of patients with diffuse sclerosis and usually within the first five years from the time of diagnosis. Risk factors for SRC include, but are not limited to, early diagnosis, corticosteroid or cyclosporine use, and the presence of anti-RNA polymerase III…

    How to Manage Pain in Patients with Renal Insufficiency or End-Stage Renal Disease on Dialysis

    October 1, 2013

    Narcotic and non-narcotic pain regimens can be used

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences